JP2013544492A - 新規な抗原結合タンパク質 - Google Patents

新規な抗原結合タンパク質 Download PDF

Info

Publication number
JP2013544492A
JP2013544492A JP2013527341A JP2013527341A JP2013544492A JP 2013544492 A JP2013544492 A JP 2013544492A JP 2013527341 A JP2013527341 A JP 2013527341A JP 2013527341 A JP2013527341 A JP 2013527341A JP 2013544492 A JP2013544492 A JP 2013544492A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013527341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544492A5 (enExample
Inventor
ニール、ジェームズ、クラーク
キョン、オー、ジョハンソン
ズデンカ、ルドミラ、ジョナク
アレクサンダー、エイチ．テイラー
クリストファー、ビー．ホプソン
スティーブン、エイチ．トゥルーリ
ズデンカ、ハスコバ
ジュディサン、エム．リー
ジョン、アール．ホワイト
ユ、シュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013544492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2013544492A publication Critical patent/JP2013544492A/ja
Publication of JP2013544492A5 publication Critical patent/JP2013544492A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013527341A 2010-09-03 2011-09-02 新規な抗原結合タンパク質 Pending JP2013544492A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37984010P 2010-09-03 2010-09-03
US61/379,840 2010-09-03
US201161440460P 2011-02-08 2011-02-08
US61/440,460 2011-02-08
PCT/US2011/050322 WO2012031198A2 (en) 2010-09-03 2011-09-02 Novel antigen binding proteins

Publications (2)

Publication Number Publication Date
JP2013544492A true JP2013544492A (ja) 2013-12-19
JP2013544492A5 JP2013544492A5 (enExample) 2014-10-23

Family

ID=45773540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527341A Pending JP2013544492A (ja) 2010-09-03 2011-09-02 新規な抗原結合タンパク質

Country Status (21)

Country Link
US (1) US9085622B2 (enExample)
EP (1) EP2611829A4 (enExample)
JP (1) JP2013544492A (enExample)
KR (1) KR20130101047A (enExample)
CN (1) CN103189391A (enExample)
AU (1) AU2011295726B2 (enExample)
BR (1) BR112013005242A2 (enExample)
CA (1) CA2809443A1 (enExample)
CL (1) CL2013000566A1 (enExample)
CO (1) CO6690769A2 (enExample)
CR (1) CR20130128A (enExample)
EA (1) EA201390328A1 (enExample)
MA (1) MA34555B1 (enExample)
MX (1) MX2013002535A (enExample)
NZ (1) NZ607680A (enExample)
PE (1) PE20140133A1 (enExample)
PH (1) PH12013500353A1 (enExample)
SG (2) SG10201401681PA (enExample)
TW (1) TW201302793A (enExample)
UY (1) UY33591A (enExample)
WO (1) WO2012031198A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538827A (ja) * 2013-10-04 2016-12-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
JP2022118731A (ja) * 2018-03-29 2022-08-15 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
TW201331225A (zh) * 2011-12-05 2013-08-01 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
EP2807272A1 (en) * 2012-01-27 2014-12-03 Ventana Medical Systems, Inc. Devices and methods for detecting bio-analytes using optically decipherable patterns
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
SMT202500020T1 (it) 2014-02-28 2025-03-12 Merus Nv Anticorpo che lega erbb-2 ed erbb-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
EP3143048B1 (en) 2014-05-14 2019-08-28 F. Hoffmann-La Roche AG Anti-her3 antibodies binding to the beta-hairpin of her3
WO2016004048A2 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
ES3047792T3 (en) * 2014-07-14 2025-12-04 Univ California Crispr/cas transcriptional modulation
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
HK1259311A1 (zh) 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
CN109328077A (zh) * 2016-06-10 2019-02-12 德国癌症研究公共权益基金会 膜联蛋白的核心结构域及其在抗原递送和接种中的用途
CN106543286A (zh) * 2016-12-07 2017-03-29 上海邦耀生物科技有限公司 一种去岩藻糖抗her2抗体及其应用
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
EP3630830A1 (en) * 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
WO2019173417A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-tip-1 antibodies and uses thereof
BR112022004789A2 (pt) * 2019-09-27 2022-06-21 Agenus Inc Proteínas heterodiméricas
US20250243261A1 (en) * 2022-04-08 2025-07-31 Cz Biohub Sf, Llc Antibody compositions and optimization methods
CN116286828B (zh) * 2023-05-12 2023-08-18 中国人民解放军军事科学院军事医学研究院 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
CN120352624B (zh) * 2025-06-25 2025-08-26 北京溯本源和生物科技有限公司 一种用于hpv18型e7蛋白检测的单克隆抗体组合及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521913A (ja) * 2005-12-30 2009-06-11 ウー３・ファルマ・アクチェンゲゼルシャフト Ｈｅｒ−３に対して誘導された抗体及びその使用

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
AU4155696A (en) 1994-11-09 1996-06-06 Regents Of The University Of California, The Immunoliposomes that optimize internalization into target cells
AU727082B2 (en) 1996-03-27 2000-11-30 Genentech Inc. ErbB3 antibodies
CA2589421C (en) 1996-03-27 2012-12-18 Genentech, Inc. Erbb3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6723694B1 (en) 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6416168B1 (en) 1997-07-15 2002-07-09 Silverbrook Research Pty Ltd Pump action refill ink jet printing mechanism
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AU2003203831B2 (en) 1998-02-04 2006-08-10 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
ATE438720T1 (de) 1998-02-04 2009-08-15 Genentech Inc Verwendung des heregulins als epithelzellenwachstumsfaktor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU2004200705A1 (en) 1998-05-15 2004-03-18 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CA2345899A1 (en) 1998-11-07 2000-05-18 Genentech, Inc. Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
JP2002544123A (ja) * 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6710186B2 (en) 1999-06-14 2004-03-23 Wisconsin Alumni Research Foundation Oligomers and polymers of di-substituted cyclic imino carboxylic acids
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7732157B1 (en) 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
MXPA02006778A (es) 2000-01-12 2004-04-05 Ventana Inc Metodo para determinar la respuesta a una terapia de cancer.
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2007216733A1 (en) 2000-04-11 2007-09-27 Genentech, Inc. Multivalent antibodies and uses therefor
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6277640B1 (en) 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US7469441B2 (en) 2000-11-24 2008-12-30 Carl Freudenberg Kg Floor mop
AU2008200400B2 (en) 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002095356A2 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1397837A2 (en) 2001-06-21 2004-03-17 Akzo Nobel N.V. Manufacturing a solar cell foil connected in series via a temporary substrate
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
DE10137374A1 (de) 2001-07-31 2003-02-27 Ipk Inst Fuer Pflanzengenetik Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2008200654B2 (en) 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
JP4132912B2 (ja) 2002-03-26 2008-08-13 日東電工株式会社 ゲル電解質とその製造方法とその利用
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
GB0225282D0 (en) 2002-10-31 2002-12-11 Astrazeneca Ab assay
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004226162A1 (en) 2003-04-04 2004-10-14 Universite De Lausanne Peptabody for cancer treatment
US7189694B2 (en) 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
US20050232931A1 (en) 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
CA2528595A1 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
US6836094B1 (en) 2003-07-01 2004-12-28 International Truck Intellectual Property Company, Llc Motor vehicle battery disconnect switch circuits
US7531649B2 (en) 2003-07-18 2009-05-12 The Regents Of The University Of California Aptamers to human epidermal growth factor receptor-3
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
WO2005013804A2 (en) 2003-08-05 2005-02-17 Euro-Celtique S.A. ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
CA2535510C (en) 2003-08-11 2013-10-15 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2005045058A2 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
US8323987B2 (en) 2004-02-17 2012-12-04 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
WO2005081898A2 (en) 2004-02-20 2005-09-09 The Trustees Of The University Of Pennsylvania Binding peptidomimetics and uses of the same
EP1796711A2 (en) 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
NZ551934A (en) 2004-06-24 2009-09-25 Inst Medical W & E Hall Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins
HRP20141111T1 (hr) 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
ZA200704888B (en) 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
DE602005025685D1 (de) * 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
WO2006068640A1 (en) 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090298195A1 (en) 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US7557181B2 (en) 2005-01-11 2009-07-07 Molecular Logix, Inc. Pan-HER antagonists and methods of use
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
ES2755976T3 (es) 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
US7718626B2 (en) 2005-02-17 2010-05-18 University Of Maryland, Baltimore ErbB3 binding protein compositions and methods of use
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
EP1856158A4 (en) 2005-03-07 2010-07-28 Targeted Molecular Diagnostics TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
WO2007038792A2 (en) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
CN101326195B9 (zh) * 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
EP1800695A1 (en) 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JP2009525048A (ja) 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
MX2008015581A (es) 2006-06-05 2008-12-17 Genentech Inc Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
CN101627053A (zh) * 2006-06-12 2010-01-13 西福根有限公司 泛细胞表面受体特异的治疗剂
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
US20100316626A1 (en) 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
US8936780B2 (en) 2006-08-30 2015-01-20 Advanced Cardiovascular Systems, Inc. Stimuli responsive polyester amide particles
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
CN101484469B (zh) 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
WO2008036802A2 (en) 2006-09-21 2008-03-27 Prometheus Laboratories Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
AU2007328427A1 (en) 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
SG177225A1 (en) 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
AU2007343610C1 (en) 2007-01-17 2013-11-07 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
EP2132227A1 (en) 2007-03-30 2009-12-16 F. Hoffmann-Roche AG Composition of labeled and non-labeled monoclonal antibodies
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
FR2915115B1 (fr) 2007-04-23 2010-09-10 Sames Technologies Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe
EP2728018B1 (en) 2007-06-01 2016-11-23 The Regents of The University of California Multigene prognostic assay for lung cancer
US8529901B2 (en) 2007-06-06 2013-09-10 Hoffmann-La Roche, Inc. Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
WO2009045579A2 (en) 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
US8501417B2 (en) 2007-06-26 2013-08-06 Vanderbilt University Immunological compositions as cancer biomarkers and/or therapeutics
EP2173377B1 (en) 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
WO2009023266A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US20090226455A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
JP2011524421A (ja) 2008-06-16 2011-09-01 イミュノジェン・インコーポレーテッド 新規の相乗効果
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US8445219B2 (en) 2008-07-25 2013-05-21 Merck Patent Gmbh Method of determination of receptor binding saturation effected by monoclonal antibodies
US8056451B2 (en) 2008-07-28 2011-11-15 Irwin Industrial Tool Company Locking pliers
US20100033482A1 (en) 2008-08-11 2010-02-11 Interactive Relighting of Dynamic Refractive Objects Interactive Relighting of Dynamic Refractive Objects
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
CN102216452B (zh) 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010051530A2 (en) 2008-10-31 2010-05-06 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US20100169729A1 (en) 2008-12-30 2010-07-01 Datta Shamanna M Enabling an integrated memory controller to transparently work with defective memory devices
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
JP2012515353A (ja) 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2010097186A1 (en) 2009-02-24 2010-09-02 Roche Diagnostic Gmbh Use of s-erbb-3 as a marker for cancer
WO2010099186A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
AU2010292897B2 (en) 2009-08-06 2016-01-07 Genentech, Inc. Method to improve virus removal in protein purification
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
KR20120059568A (ko) 2009-08-21 2012-06-08 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도
EP2475390A4 (en) 2009-09-09 2014-01-01 Quintiles Transnat Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP2013507378A (ja) 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
EP2542699A4 (en) 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
WO2011139629A2 (en) 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
CA2799217A1 (en) 2010-05-13 2011-11-17 Fox Chase Cancer Center Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
AU2012211258A1 (en) 2011-01-27 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-ErbB3 antibodies
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
WO2012106587A1 (en) 2011-02-04 2012-08-09 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
JP2014509850A (ja) 2011-03-06 2014-04-24 メルク セロノ ソシエテ アノニム 低フコース細胞株およびその使用
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521913A (ja) * 2005-12-30 2009-06-11 ウー３・ファルマ・アクチェンゲゼルシャフト Ｈｅｒ−３に対して誘導された抗体及びその使用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538827A (ja) * 2013-10-04 2016-12-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
US10179815B2 (en) 2013-10-04 2019-01-15 Ventana Medical Systems, Inc. Antibodies specifically binding to HER3
JP2022118731A (ja) * 2018-03-29 2022-08-15 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP7545437B2 (ja) 2018-03-29 2024-09-04 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP2024164153A (ja) * 2018-03-29 2024-11-26 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP7825000B2 (ja) 2018-03-29 2026-03-05 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Also Published As

Publication number Publication date
CO6690769A2 (es) 2013-06-17
WO2012031198A2 (en) 2012-03-08
KR20130101047A (ko) 2013-09-12
WO2012031198A3 (en) 2012-05-18
MA34555B1 (fr) 2013-09-02
EA201390328A1 (ru) 2013-08-30
TW201302793A (zh) 2013-01-16
CL2013000566A1 (es) 2014-01-24
MX2013002535A (es) 2013-06-03
SG187930A1 (en) 2013-03-28
AU2011295726A1 (en) 2013-03-21
US9085622B2 (en) 2015-07-21
AU2011295726B2 (en) 2014-11-06
SG10201401681PA (en) 2014-07-30
NZ607680A (en) 2015-02-27
EP2611829A4 (en) 2014-05-07
EP2611829A2 (en) 2013-07-10
CN103189391A (zh) 2013-07-03
CA2809443A1 (en) 2012-03-08
BR112013005242A2 (pt) 2016-06-28
PE20140133A1 (es) 2014-02-09
US20130156779A1 (en) 2013-06-20
CR20130128A (es) 2013-06-28
PH12013500353A1 (en) 2013-03-25
UY33591A (es) 2012-03-30

Similar Documents

Publication Publication Date Title
US9085622B2 (en) Antigen binding proteins
JP7062704B2 (ja) アゴニスト性ｉｃｏｓ結合タンパク質
WO2016059602A2 (en) Methods of treating cancer and related compositions
CN113166245B (zh) SIRPα结合蛋白及其使用方法
CN109475602B (zh) 抗pd-l1和il-2细胞因子
KR101721678B1 (ko) 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
US20230295313A1 (en) Il1rap binding proteins
AU2017204686B2 (en) Compositions and methods for detecting and treating esophageal cancer
TWI873112B (zh) 與TfR結合之雙專一性抗體
CN113195539A (zh) 药物组合
CN116940597A (zh) 多特异性抗体及其用途
JP2022529232A (ja) 抗ｈｅｒ２結合分子
KR20220103961A (ko) 약제학적 조합물 및 이의 용도
TW202216788A (zh) 與GPC3及TfR結合之雙特異性抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160902

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170404